[ Inside the business ]

MDT stock analysis

MDT · Medtronic Plc

Electromedical and electrotherapeutic apparatus. Growing 14%. Keeps 18¢ of every dollar.

Watch: a leadership change.

The future, in 7 questions

Priced in: 1.4× sales in 5 yrs. Evidence: sales +14% · 18¢ profit/$1.

01 What's priced in?1.4× sales in 5 yrs
Sales now$37.5B
Needed in 5 yrs$51.6B
Backlog$400M
02 Is the wave rising?Neurotechnology · 0.9×
'20'21'22'23'24'2542
#8 of 20 mentioning it
03 Will customers keep buying?Sales +14%, speeding up
No customer over 10%
Backlog $400M · under 0.1× salesPrepaid $500MSales +14%, speeding up
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 18¢ per $1, rising
'22'23'24'25'2618¢
Before running costs: 66% → 65%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −1.6%/yrDebt $2.5B
07 What could break it?1 to watch
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +9%, +10%, then +14% vs. a year ago. A leadership change was filed on Oct 19.

What could go wrong

Steadier than most.

It has moved 0.7× the market. In the 2008 crisis it fell 36% while the market fell 51%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

18¢ profit.

35¢ to make what it sells, 47¢ on research and overhead, 18¢ left over. Revenue $37.5B in the last 12 months.

Its market

0.6× the economy.

The government expects its industry, navigational, measuring, electromedical, and control instruments manufacturing, to grow 1.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 154¢ of each $1 of profit.

Competitive advantage

7 of 10 years.

Returns beat its 7.1% cost of capital in 7 of the last 10 years. Gross margin went from 69% to 65%.

Future bets

8% on research.

$2.9B a year on R&D. $1.9B on equipment and buildings.

All figures from Medtronic Plc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.